In contrast to pPCa, metastatic tumors harboring CDK12 alterations expressing low levels of MHC-I/II showed allele-specific copy number gains in the MHC-I/II complex and key regulators of MHC expression (Table 3 and Figure S4). This evidence concerns the gene CDK12 and metastatic neoplasm.